Catalog No.
Product Name
Application
Product Information
Citations
-
α-glucosidase/Acetylcholinesterase Inhibitor
7β-Hydroxybufalin is a bufadienolide that acts as a potent inhibitor of α-glucosidase and acetylcholinesterase. Isolated from the venom of Bufo bufo gargarizans, this compound demonstrates significant biological activity relevant to the modulation of carbohydrate and neurotransmitter metabolism. 7β-Hydroxybufalin is utilized in research applications focused on metabolic disorders and neurodegenerative diseases. -
Insecticide
Metolcarb is an N-methylcarbamate insecticide that functions by inhibiting acetylcholinesterase, leading to the accumulation of acetylcholine and consequent disruption of neural transmission in pest organisms. This compound is utilized in agricultural practices to effectively manage various insect populations, enhancing crop protection. Its efficacy in targeting insects makes it a valuable tool in integrated pest management strategies. -
Racemate of Anabasine
(±) Anabasine hydrochloride is a racemic mixture of the alkaloid Anabasine, functioning primarily as an agonist of the alpha-7 nicotinic acetylcholine receptor (α7nAChR). This compound demonstrates notable anti-inflammatory properties, making it useful in studies related to inflammation and neuropathology. Additionally, it exhibits insecticidal activity, proving beneficial in entomological research. -
sEH/AChE Inhibitor
sEH/AChE-IN-3 is a potent dual inhibitor of soluble epoxide hydrolase (sEH) and acetylcholinesterase (AChE), demonstrating IC50 values of 0.4 nM for human sEH and 1.94 nM for human AChE. This compound also exhibits inhibitory activity against human butyrylcholinesterase with an IC50 of 615 nM, and shows strong inhibition in both mouse sEH and AChE with IC50 values of 4.3 nM and 2.61 nM, respectively. Due to its ability to penetrate the blood-brain barrier, sEH/AChE-IN-3 is suitable for research applications in neuropharmacology and the study of neurological disorders. -
sEH/AChE Inhibitor
sEH/AChE-IN-4 is a potent dual inhibitor targeting soluble epoxide hydrolase (sEH) and acetylcholinesterase (AChE). It demonstrates impressive inhibitory activity with IC50 values of 3.1 nM against human sEH, 1660 nM against human AChE, 179 nM against human butyrylcholinesterase (hBChE), 14.5 nM against murine sEH, and 102 nM against murine AChE. This compound has potential applications in research areas related to neurodegenerative diseases and pain modulation, effectively crossing the blood-brain barrier. -
Drug Derivative
Fenthion sulfone is a drug derivative primarily recognized for its potential as a pesticide metabolite. It exhibits significant biological activity by interacting with cholinesterase enzymes, leading to the inhibition of acetylcholine breakdown. This compound is utilized in research applications related to toxicology and environmental studies, particularly in assessing the effects of organophosphate compounds on biological systems. -
CerS6 Inhibitor, Ceramide Synthesis Inhibitor, Acetylcholinesterase Inhibitor
FF-C1 is a non-competitive inhibitor of Ceramide Synthase 6 (CerS6), exhibiting an IC50 of 7.89 μM. By inhibiting intestinal CerS6, FF-C1 effectively lowers serum ceramide levels, offering protective effects against metabolic dysfunction-associated steatohepatitis. This compound is also reported to inhibit acetylcholinesterase, highlighting its potential applications in studying metabolic disorders and neurodegenerative diseases. -
Endogenous Metabolite
4-Chloro-N,N-diisopropylbenzamide is an amide with significant relevance as a substrate for cytochrome P450 enzymes in vivo and for acetylcholinesterase in vitro. This compound plays a crucial role in metabolic studies, enabling the investigation of enzyme kinetics and substrate specificity. Its application extends to research focused on drug metabolism and neuropharmacology. -
Endogenous Metabolite
Tetrachlorvinphos is an organophosphorus compound that primarily acts as a cholinesterase inhibitor. This metabolite is commonly utilized in agricultural settings for pest control due to its effectiveness against a variety of insects. With low toxicity to mammals, tetrachlorvinphos serves as a useful tool for studying pesticide interactions and their effects on non-target organisms. -
Stable Isotope
(Z)-Tetrachlorvinphos-d6 is a deuterated form of Tetrachlorvinphos, an organophosphorus pesticide that primarily acts as a cholinesterase inhibitor. This stable isotope is utilized in research to trace metabolic pathways and analyze pesticide residues in various biological matrices. With low toxicity to mammals, it provides a safe and useful tool for studying the environmental impact and biochemical interactions of pesticide application. -
Endogenous Metabolite
Bendiocarb is a carbamate compound that primarily acts as an inhibitor of the enzyme acetylcholinesterase. This inhibition results in increased levels of acetylcholine, which plays a crucial role in neurotransmission and muscle contraction. Bendiocarb is utilized in research applications focusing on neurobiology and the study of cholinergic systems, as well as in the examination of potential neurotoxic effects. -
Endogenous Metabolite
Neostigmine iodide is a reversible inhibitor of acetylcholinesterase, enhancing muscle tone and function. This compound is primarily utilized in the management of myasthenia gravis, aiming to improve muscle strength in affected patients. Additionally, Neostigmine iodide is employed in anesthetic procedures to counteract the effects of nondepolarizing muscle relaxants, such as rocuronium, thereby facilitating recovery from anesthesia. -
Endogenous Metabolite
BuChE-IN-14 is a selective inhibitor of acetylcholinesterase (AChE), primarily targeting endogenous metabolite pathways. In vitro studies demonstrated a concentration-dependent inhibition of AChE activity in rat brain tissue, leading to increased extracellular acetylcholine (ACh) levels in the hippocampus and striatum. This compound shows potential for addressing memory impairments linked to cholinergic dysfunction, making it valuable for research into neurodegenerative diseases and cognitive enhancement. -
Methyltransferase
Catechol O-methyltransferase (COMT), derived from porcine liver, is a methyltransferase that facilitates the magnesium-dependent transfer of methyl groups from S-adenosyl methionine to the hydroxyl group of dopamine, resulting in the formation of 3-methoxytyramine. This enzyme exists in two forms: a soluble form (S-COMT) and a membrane-bound form (MB-COMT). COMT plays a critical role in regulating the levels of key neurotransmitters, including epinephrine, norepinephrine, and dopamine, making it essential for research related to neuropharmacology and psychiatric disorders. -
Isotope-Labeled Compounds
(±) Anabasine-d4 is a deuterated analog of (±) Anabasine, serving as a useful isotope-labeled compound. This racemic mixture acts as an agonist of the α7 nicotinic acetylcholine receptor (α7nAChR), demonstrating notable anti-inflammatory properties and insecticidal activity. It is suitable for applications in pharmacological research, particularly studies involving receptor activation and inflammatory responses. -
Cholinesterase (ChE) Inhibitor
Vomifoliol is a cholinesterase (ChE) inhibitor that exhibits significant antiacetylcholinesterase activity, comparable to that of abscisic acid (ABA). Additionally, this compound shows moderate antileishmanial activity, making it a valuable tool for research into neurodegenerative disorders and parasitic infections. Its unique structure, featuring a modified 2,4-pentadiene side chain, further contributes to its biological activity, offering potential applications in pharmacological studies. -
Acetylcholinesterase Inhibitor
Trimethylammonium chloride is a non-competitive inhibitor of acetylcholinesterase, targeting the enzymatic activity responsible for the hydrolysis of the neurotransmitter acetylcholine. By reversibly blocking the deacetylation process of acetylcholinesterase, this reagent plays a critical role in studies related to neurobiology and the modulation of synaptic transmission. Its application extends to research investigating cholinergic signaling pathways and potential therapeutic strategies for neurological disorders. -
Racemate of Anabasine
(±) Anabasine is the racemic mixture of Anabasine, acting as an agonist of the alpha-7 nicotinic acetylcholine receptor (α7nAChR). This compound has demonstrated anti-inflammatory properties and insecticidal activity, making it relevant for research in neuropharmacology and pest control studies. Its biological activities encourage further investigations into its therapeutic potential and applications. -
Monoamine Oxidase Inhibitor
MAO-B-IN-2 is a selective and competitive inhibitor of monoamine oxidase B (MAO-B) with an IC50 value of 0.51 μM, and it also inhibits butyrylcholinesterase (BChE) with an IC50 of 7.00 μM. This compound plays a significant role in studying neurodegenerative disorders by modulating monoamine metabolism, making it valuable for research into conditions such as Parkinson's disease and Alzheimer's disease. Its specificity for MAO-B makes it an important tool for exploring therapeutic pathways involving neurotransmitter regulation. -
NF-κB Activator
Methylchloroisothiazolinone is a potent NF-κB activator known for its pro-inflammatory properties. It induces the expression of pro-inflammatory cytokines, including IL-1β, TNF-α, and IL-6, through the activation of the NF-κB signaling pathway and upregulation of TLR4. This compound is utilized in research focusing on allergic contact dermatitis and immunotoxicity mechanisms. Additionally, Methylchloroisothiazolinone demonstrates neurotoxic effects and has been shown to impair cholinesterase activity, leading to increased oxidative stress and detrimental impacts on aquatic organisms, specifically Mediterranean mussels. -
NF-κB Inhibitor
6-O-p-Hydroxybenzoylglutinoside is a selective NF-κB inhibitor that effectively suppresses TNF-α-activated NF-κB transcriptional activity, with an IC50 of 52.78 μM. This compound demonstrates targeted biological activity without significantly inhibiting soluble epoxide hydrolase (sEH), acetylcholinesterase (AChE), or butyrylcholinesterase (BChE). Isolated from the seeds of Catalpa bungei (Manchurian catalpa), 6-O-p-Hydroxybenzoylglutinoside is valuable for research applications focused on inflammation and signal transduction pathways. -
Anesthesia Agent
Desflurane is a volatile anesthetic agent that functions primarily by enhancing the inhibitory effects of gamma-aminobutyric acid (GABA) at the GABA receptor, resulting in dose-dependent anesthesia. It is utilized in both surgical and diagnostic procedures requiring general anesthesia, offering rapid onset and recovery profiles. Additionally, desflurane is notable for its minimal metabolism, making it a valuable option in procedures requiring quick emergence from anesthesia. Its properties also make it suitable for studying the effects of anesthetics on neuronal activity. -
Aβ Aggregation Inhibitor
Aβ-IN-5 is a potent Aβ aggregation inhibitor, demonstrating oral bioavailability. It effectively inhibits acetylcholinesterase (AChE) and butyrylcholinesterase (BuChE) with IC50 values of 21.29 μM and 1.32 μM, respectively. This compound exhibits significant neuroprotective effects while maintaining low neurotoxicity, making it a valuable tool for research on neurodegenerative diseases, particularly Alzheimer’s disease. -
Cholinesterase (ChE) Inhibitor
hAChE/Aβ1-42-IN-1 is a potent cholinesterase (ChE) inhibitor that effectively inhibits human acetylcholinesterase (hAChE) and prevents the aggregation of Aβ1-42 peptides. This compound demonstrates favorable relative safety in HepG2 cell lines and exhibits excellent blood-brain barrier (BBB) penetration, exhibiting a wide safety margin. hAChE/Aβ1-42-IN-1 is a valuable tool for research focusing on Alzheimer's disease (AD) and related neurodegenerative conditions. -
Antidepressant Agent
Protriptyline is a potent tricyclic antidepressant (TCA) primarily targeting neurotransmitter reuptake mechanisms. It exhibits significant inhibition of acetylcholinesterase (AChE) activity, with an IC50 value of 0.06 mM, and effectively disrupts Aβ self-assembly. This compound is utilized in research focused on depression and Alzheimer’s disease, providing insights into therapeutic strategies for these conditions. -
BuChE Inhibitor
BuChE-IN-6 is a potent and selective inhibitor of butyrylcholinesterase (BuChE), exhibiting IC50 values of 0.46 μM and 0.51 μM for equine and human BuChE, respectively. This compound also demonstrates the ability to inhibit self-aggregation of amyloid-beta 42 (Aβ42), making it a valuable tool for research related to neurodegenerative diseases. Its unique properties support investigations into cholinergic dysfunction and the pathogenesis of Alzheimer's disease. -
hAChE/hBACE Inhibitor
hAChE/hBACE-1-IN-4 is a quinazoline derivative that functions as a dual inhibitor of human acetylcholinesterase (hAChE) and human β-site amyloid precursor protein cleaving enzyme 1 (hBACE-1). It exhibits potent inhibitory activity with IC50 values of 0.283 μM for hAChE and 0.231 μM for hBACE-1. This compound demonstrates the ability to inhibit amyloid-beta (Aβ) aggregation and shows favorable properties such as non-neurotoxicity, blood-brain barrier permeability, and oral bioavailability. hAChE/hBACE-1-IN-4 is suitable for research applications related to Alzheimer's disease. -
AChE Inhibitor
AChE-IN-19 is a potent inhibitor of acetylcholinesterase (AChE), exhibiting an IC50 value of 0.56 μM. This compound also demonstrates the ability to inhibit amyloid beta (Aβ) aggregation, contributing to its neuroprotective properties. AChE-IN-19 has been shown to exert minimal toxicity on SH-SY5Y neuronal cells, making it a valuable tool for research applications related to Alzheimer's disease. -
Amyloid-β Inhibitor
AChE/Aβ-IN-5 is a bifunctional inhibitor that targets acetylcholinesterase (AChE) and reduces the auto-induced aggregation of amyloid-β (Aβ) peptides. This compound has demonstrated the ability to significantly ameliorate cognitive deficits induced by scopolamine and Aβ in murine models. It serves as a valuable tool for research into neurodegenerative diseases, particularly Alzheimer's disease, by providing insights into the mechanisms underlying cognitive impairment. -
AChE Inhibitor
Memoquin is an AChE inhibitor with significant anti-amyloid and antioxidant properties. It exhibits oral bioavailability and selectively inhibits BACE-1 and AChE, with IC50 values of 108 nM and 1.55 nM, respectively. Memoquin is noted for its ability to enhance cognitive function while preventing Aβ-induced neurotoxicity associated with oxidative stress. This compound is valuable for research into Alzheimer's disease and related neurodegenerative disorders. -
AChE Inhibitor
Phenserine tartrate is a selective, noncompetitive inhibitor of acetylcholinesterase (AChE) derived from Physostigmine. This compound has been shown to reduce the formation of β-amyloid precursor protein (APP) and β-amyloid peptide (Aβ), key factors involved in Alzheimer's disease pathology. Phenserine tartrate has demonstrated potential in improving cognitive performance and may help slow the progression of Alzheimer's disease, making it a valuable tool for research in neurodegenerative disorders. -
ChE/Aβ1-42 Aggregation Inhibitor
ChE/Aβ1-42-IN-1 is a potent inhibitor of acetylcholinesterase (AChE), butyrylcholinesterase (BuChE), and amyloid-beta peptide (Aβ1-42) aggregation, exhibiting IC50 values of 0.062 µM, 0.767 µM, and 1.227 µM, respectively. This compound demonstrates significant blood-brain barrier (BBB) penetration, making it a promising candidate for research into Alzheimer's disease. ChE/Aβ1-42-IN-1's multi-targeted mechanism positions it as a valuable tool for studying therapeutic strategies in neurodegenerative disorders. -
AChE Inhibitor
hAChE-IN-10 is a potent inhibitor of human acetylcholinesterase (AChE), demonstrating an IC50 of 6.34 nM. This compound exhibits significant antioxidant properties and effectively scavenges free radicals. Additionally, hAChE-IN-10 has been shown to inhibit Cu2+-induced aggregation of Aβ1-42, reduce amyloid plaque formation, and provide neuroprotective effects. It has also been linked to the improvement of cognitive deficits in mouse models induced by scopolamine, making it a valuable tool for studying neurodegenerative diseases and cognitive impairment. -
MAO-B Inhibitor
MAO-B-IN-50 is a selective inhibitor of monoamine oxidase B (MAO-B), demonstrating an IC50 value of 0.06 μM. This compound is effective in inhibiting the aggregation of amyloid-beta (Aβ40/42) and Tau proteins, with overall IC50 values near 1 μM. Additionally, MAO-B-IN-50 shows potent selective inhibition of acetylcholinesterase (AChE) with an IC50 of 1.78 μM. It is suitable for use in research related to Alzheimer's disease. -
AChE Inhibitor
AChE-IN-12 is a selective acetylcholinesterase (AChE) inhibitor that effectively penetrates the blood-brain barrier, exhibiting IC50 values of 0.41 μM for rat AChE and 1.88 μM for electric eel AChE. This compound also demonstrates antioxidant properties (ORAC = 3.3 eq), selectively chelates metals, and inhibits human monoamine oxidase B (MAO-B) with an IC50 of 8.8 μM. AChE-IN-12 significantly inhibits both self- and Cu2+-induced aggregation of Aβ1-42 and displays neuroprotective effects, making it a valuable tool for research related to Alzheimer’s disease. -
AChE/BuChE Inhibitor
AChE/BuChE-IN-3 is a dual inhibitor of acetylcholinesterase (AChE) and butyrylcholinesterase (BuChE), exhibiting IC50 values of 0.65 μM and 5.77 μM, respectively. This compound effectively inhibits the aggregation of amyloid beta peptide Aβ1-42 and demonstrates neuroprotective properties with minimal toxicity in SH-SY5Y cells. AChE/BuChE-IN-3 is suitable for research applications related to Alzheimer's disease, providing insight into cholinergic system modulation and potential therapeutic strategies. -
Aβ1-42/AChE Inhibitor
AChE-IN-59 is a potent acetylcholinesterase (AChE) inhibitor, displaying an IC50 value of 0.05 μM. This compound effectively inhibits the aggregation of amyloid-beta peptide Aβ1-42, offering protective effects on neuronal cells and demonstrating favorable penetration of the blood-brain barrier. AChE-IN-59 is a valuable tool for research focused on Alzheimer's disease and related neurodegenerative disorders. -
AChE Inhibitor
AP2238 is a dual-function acetylcholinesterase (AChE) inhibitor that demonstrates Ki values of 21.7 μM for human AChE and 48.9 μM for butyrylcholinesterase (BuChE). This compound effectively inhibits the pro-fibrotic interaction between the peripheral site of AChE and amyloid-beta (Aβ), as well as Aβ aggregation. AP2238 is primarily utilized in Alzheimer's disease research, contributing to studies focused on neurodegeneration and cholinergic dysfunction. -
AChE/BuChE Inhibitor
AChE/BuChE-IN-2 is a selective inhibitor of acetylcholinesterase (AChE) and butyrylcholinesterase (BuChE), demonstrating IC50 values of 0.72 μM and 0.16 μM, respectively. This compound exhibits non-competitive inhibition of AChE and effectively inhibits β-amyloid (Aβ) aggregation, with an IC50 of 62.52 μM. Notably, AChE/BuChE-IN-2 is capable of crossing the blood-brain barrier, making it a valuable tool for studying neurodegenerative conditions, such as Alzheimer's disease. -
BuChE Inhibitor
Multitarget AD inhibitor-1 is a selective and reversible inhibitor of butyrylcholinesterase (BuChE), exhibiting IC50 values of 7.22 μM for human BuChE and 1.55 μM for equine BuChE. This compound also inhibits β-secretase activity (IC50 = 41.60 μM) and demonstrates a strong capacity to inhibit amyloid β aggregation (IC50 = 3.09 μM) as well as tau aggregation. As a diphenylpropylamine derivative, it holds promise for multifunctional disease-modifying applications in Alzheimer’s research. -
AChE Inhibitor
hAChE-IN-3 is a potent acetylcholinesterase (AChE) inhibitor with demonstrated blood-brain barrier permeability. It exhibits significant inhibitory effects against butyrylcholinesterase (BuChE), monoamine oxidase B (MAO-B), and β-site amyloid precursor protein cleaving enzyme 1 (BACE-1), with IC50 values of 0.44, 0.08, 5.15, and 0.38 μM, respectively. Additionally, hAChE-IN-3 possesses antioxidant properties and metal chelating ability, enabling it to interact with peripheral anion sites and influence β-amyloid accumulation. This compound holds promise for advancing research in Alzheimer's disease and related neurodegenerative disorders. -
Multi-target Inhibitor
AChE-IN-63 is a multi-target inhibitor with a primary action as a selective inhibitor of human acetylcholinesterase (hAChE), exhibiting an IC50 of 0.103 μM. This compound also demonstrates inhibitory activity against human butyrylcholinesterase (hBChE) and human beta-site amyloid precursor protein cleaving enzyme 1 (hBACE-1) with IC50 values of 10 μM and 1.342 μM, respectively. AChE-IN-63 effectively inhibits Aβ aggregation, thereby preventing the formation and deposition of Aβ1-42. Due to its ability to penetrate the blood-brain barrier and oral bioavailability, it is primarily utilized in research related to Alzheimer's disease. -
BChE Inhibitor
BChE-IN-8 is a potent and orally active inhibitor of butyrylcholinesterase (BChE), demonstrating IC50 values of 0.15 nM against equine serum BChE and 45.2 nM against human BChE. Its high stability ensures enhanced blood concentration and tissue exposure. BChE-IN-8 exhibits neuroprotective and cognitive-enhancing effects through modulation of the cholinergic system, amyloid beta (Aβ) aggregation, and neuropeptide levels. This compound is particularly relevant for research into Alzheimer's disease. -
AChE/MAO-B Inhibitor
AChE/MAO-B-IN-9 is a selective, reversible, non-competitive inhibitor of acetylcholinesterase (AChE) and monoamine oxidase B (MAO-B), exhibiting an IC50 of 0.156 μM against electric eel AChE. This compound effectively inhibits the formation of Aβ40/42 fibrils, promotes the depolymerization of Aβ fibrils, and suppresses Tau protein fibril formation. Additionally, AChE/MAO-B-IN-9 demonstrates antioxidant and neuroprotective properties, while alleviating memory deficits induced by scopolamine in murine models. This reagent is valuable for research related to Alzheimer’s disease. -
AChE Inhibitor
AChE-IN-88 is a novel pyridazine derivative that functions as an acetylcholinesterase (AChE) inhibitor. It exhibits potent inhibitory activity against AChE and additionally targets amyloid β protein (Aβ) aggregation, making it relevant for Alzheimer's disease research. With a pIC50 value of 7.16, AChE-IN-88 is a promising candidate for studying multi-target approaches in neurodegenerative conditions. -
BuChE Inhibitor
BuChE-IN-2 is a potent inhibitor of butyrylcholinesterase (BuChE), exhibiting IC50 values of 1.28 μM and 0.67 μM against BuChE and nitric oxide production, respectively. This compound has demonstrated the ability to inhibit amyloid-beta aggregation, reduce reactive oxygen species formation, and chelate copper ions, all while effectively crossing the blood-brain barrier. BuChE-IN-2 is a valuable tool for research focused on Alzheimer's disease and related neurodegenerative disorders. -
Stable Isotope
Methyl tridecanoate-d25 is a deuterium-labeled derivative of methyl tridecanoate, functioning as a stable isotope. This compound exhibits moderate inhibition of β-amyloid aggregation, making it relevant for studies related to neurodegenerative diseases. Additionally, it shows weak inhibition of acetylcholinesterase (AChE), offering potential applications in enzyme activity assays and the investigation of cholinergic signaling. -
ChE Inhibitor
Aβ1–42 aggregation inhibitor 3 is a potent inhibitor of acetylcholinesterase (AChE) and butyrylcholinesterase (BuChE), with IC50 values of 1.634 μM and 0.0285 μM, respectively. This compound effectively inhibits the aggregation of Aβ1-42, making it a valuable tool in Alzheimer's disease research. Its dual inhibitory action on cholinesterases positions it as a promising candidate for studies aimed at understanding and mitigating neurodegenerative processes associated with AD. -
hBChE Inhibitor
hBChE-IN-1 is a potent inhibitor of human butyrylcholinesterase (hBChE) with an IC50 value of 7 nM, demonstrating high selectivity over human acetylcholinesterase (hAChE). This compound also exhibits inhibitory activity against tau and Aβ40 protein aggregation, with IC50 values of 20 μM and 4.3 μM, respectively. hBChE-IN-1 is valuable in Alzheimer's disease research, aiding in the exploration of therapeutic strategies targeting protein aggregation associated with neurodegeneration. -
Phenserine Racemic Form
(±)Phenserine is a racemic form of the acetylcholinesterase (AChE) inhibitor Phenserine, derived from Physostigmine. This compound exhibits non-competitive and long-lasting inhibition of AChE, leading to a decrease in the formation of β-amyloid precursor protein (APP) and β-amyloid peptide (Aβ). (±)Phenserine has been shown to enhance cognitive abilities and may help to slow the progression of Alzheimer's disease, making it a valuable agent in neurodegenerative research.
